RA Capital Management L.P. Acquires 168,752 Shares of Ascendis Pharma A/S $ASND

Key Points

• RA Capital Management L.P. increased its stake in Ascendis Pharma A/S by 1.7% in Q1, owning 10,281,496 shares, which now represent approximately 26.8% of its portfolio.
• Ascendis Pharma A/S reported a quarterly earnings per share of ($0.93), surpassing analysts' expectations of ($1.42) with revenue hitting $216.28 million.
• Analysts have a consensus rating of "Buy" for Ascendis Pharma A/S, with the average price target recently raised to $243.36.

RA Capital Management L.P. increased its holdings in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 1.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 10,281,496 shares of the biotechnology company's stock after purchasing an additional 168,752 shares during the quarter. Ascendis Pharma A/S accounts for about 26.8% of RA Capital Management L.P.'s holdings, making the stock its largest holding. RA Capital Management L.P. owned 16.86% of Ascendis Pharma A/S worth $1,602,474,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Braidwell LP acquired a new position in shares of Ascendis Pharma A/S during the first quarter valued at approximately $16,632,000. Point72 Europe London LLP purchased a new position in shares of Ascendis Pharma A/S during the first quarter worth $1,879,000. Quarry LP raised its stake in shares of Ascendis Pharma A/S by 371.4% in the first quarter. Quarry LP now owns 3,300 shares of the biotechnology company's stock valued at $514,000 after acquiring an additional 2,600 shares in the last quarter. Vident Advisory LLC acquired a new stake in shares of Ascendis Pharma A/S in the first quarter valued at $273,000. Finally, Driehaus Capital Management LLC raised its stake in Ascendis Pharma A/S by 71.6% in the first quarter. Driehaus Capital Management LLC now owns 151,829 shares of the biotechnology company's stock valued at $23,664,000 after buying an additional 63,333 shares in the last quarter.

Analyst Ratings Changes

A number of research firms have recently commented on ASND. JPMorgan Chase & Co. lifted their target price on Ascendis Pharma A/S from $254.00 to $260.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 19th. Royal Bank Of Canada lifted their price objective on Ascendis Pharma A/S from $210.00 to $230.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Wedbush lifted their price objective on Ascendis Pharma A/S from $212.00 to $220.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Bank of America lifted their price target on shares of Ascendis Pharma A/S from $227.00 to $230.00 and gave the company a "buy" rating in a research report on Tuesday. Finally, Cowen restated a "buy" rating on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Fifteen investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $244.36.

Ascendis Pharma A/S Trading Up 3.9%

NASDAQ:ASND traded up $7.78 on Friday, reaching $205.91. The stock had a trading volume of 461,010 shares, compared to its average volume of 487,399. The company has a 50-day moving average of $182.68 and a 200 day moving average of $167.87. The stock has a market cap of $12.60 billion, a P/E ratio of -39.91 and a beta of 0.39. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $207.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating analysts' consensus estimates of ($1.42) by $0.49. The firm had revenue of $216.28 million during the quarter, compared to analysts' expectations of $163.17 million. On average, equities analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.